Enzymatica
Enzymatica is a Swedish life science company that develops and sells medical products for infection-related conditions based on its Penzyme barrier technology. Its core product is ColdZyme, a mouth spray for colds and cold-like symptoms, and the business is organized around in-house enzyme production, regulatory know-how, and partner-led commercialization in selected markets.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueMouth spray products based on barrier technology for colds and cold-like symptoms.
Internal production of marine enzymes and related know-how that support the product platform.
Documentation, approvals, and scientific support used to maintain market access and partnerships.
Customers
Enzymatica sells primarily into consumer health channels, where end users buy ColdZyme for relief from colds and upper respiratory symptoms. Commercial partners, distributors, and local market operators are also key customers because they handle marketing, sales, and distribution in many countries. In Sweden, the UK, and Iceland, the company also manages sales and marketing directly, giving it direct access to consumers and market feedback.
Buy ColdZyme for symptom relief and convenience in self-care settings
Buy rights, supply, and support to market and distribute ColdZyme locally
Stock the product for over-the-counter consumer purchase and repeat use
Purchase through markets where Enzymatica manages sales and marketing directly
Strategy
Enzymatica’s strategy is built around expanding through local partners, relaunching ColdZyme in markets where it already has MDR approval, and broadening the product portfolio around its barrier technology. Scientific evidence, regulatory documentation, and partner selection are central to the model because they support market access and brand credibility in regulated consumer health markets.
Local partners provide market access, sales capability, and regulatory familiarity without requiring a large local footprint
Existing MDR approvals can shorten time to market and improve the economics of re-entry
A broader portfolio can reduce dependence on a single product and extend the barrier-technology platform
Clinical evidence and documentation support approvals, partner discussions, and consumer trust
Geography
Enzymatica is headquartered in Lund, Sweden, with key operational functions also in Reykjavik, Iceland. The company commercializes through partners across international markets, with direct sales and marketing in Sweden, the United Kingdom, and Iceland, and it is focused on relaunching and expanding in selected EEA and other priority cold-remedy markets.
Risks
Enzymatica depends on external financing, partner execution, and continued regulatory acceptance in markets where medical-device rules can change. The business also faces competition from larger consumer-health companies, IT and cybersecurity exposure, and production/supply-chain risks because manufacturing is split between in-house enzyme production and external contract manufacturing.
- Funding and capital accessImpact: HighLikelihood: High
The company needs external financing to fund research, regulatory work, and market expansion
Exposure: Corporate strategy execution
- Partner distribution dependenceImpact: HighLikelihood: High
Sales in many markets rely on third-party partners, so weak partner execution directly limits revenue
Exposure: International commercialization
- Regulatory and classification riskImpact: HighLikelihood: Medium
Medical-device rules, approvals, and product classification can change market access and documentation needs
Exposure: EU/EEA and other regulated markets
- Production and supply-chain dependenceImpact: MediumLikelihood: Medium
The model combines in-house enzyme production with external filling and packaging partners
Exposure: Manufacturing and fulfillment
- CompetitionImpact: Medium
Larger rivals may offer stronger brands, lower prices, or more effective products
Exposure: Cold-remedy consumer health markets
- Cybersecurity and IT disruptionImpact: Medium
Production, quality, and communication depend on functioning systems and data protection
Exposure: Operations and compliance
Accounting
Judgemental itemsQuarterly judgment determines which R&D costs are recognized as assets versus expenses
Impact: Can materially affect operating profit and balance-sheet intangibles
The group reports significant goodwill from acquisitions and must test it annually
Impact: Impairment could reduce equity and earnings materially
International expansion increases exposure to transaction and translation effects
Impact: Can create volatility in reported results and equity reserves
Final formulation, filling, and packaging are outsourced in part, affecting cut-off and cost recognition
Impact: Can influence gross margin and inventory valuation
Similar listed companies
Publicly listed companies with a comparable business focus.
eXoZymes Inc
EXOZ · Biological Products, (No Diagnostic Substances)
Enanta Pharmaceuticals, Inc
ENTA · Pharmaceutical Preparations
Enanta Pharmaceuticals is a U.S.-based biotechnology company focused on discovering and developing small-molecule drugs in virology and immunology.
Halozyme Therapeutics, Inc
HALO · Biological Products, (No Diagnostic Substances)
Halozyme Therapeutics is a biopharmaceutical company built around drug-delivery technologies rather than a broad portfolio of branded medicines.
Tiziana Life Sciences Ltd
TLSA · Pharmaceutical Preparations
Tiziana Life Sciences Ltd is a U.S.-listed biotechnology company focused on developing antibody-based therapies, with its lead program centered on intranasal foralumab.
Essity B
ESSITY-B · Consumer Staples
Essity Aktiebolag (publ) is a global hygiene and health company that develops, produces, and sells personal care and tissue products.
Innoviva, Inc.
INVA · Pharmaceutical Preparations
Last updated: 24/09/2026